U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06985472) titled 'Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL' on Nov. 13, 2024.
Brief Summary: This is a multi-center, prospective cohort study. The main purpose of study is to evaluate the efficacy and safety of Orelabrutinib combined with Zuberitamab in the initial treatment of MZL Main efficacy indicators Complete response rate (CR) at the end of combination therapy.
Study Start Date: Nov. 13, 2024
Study Type: INTERVENTIONAL
Condition:
Initial MZL
Untreated MZL
BTKi
CD20
Intervention:
DRUG: ZO
Orelabrutinib 150mg, po, gd, D1-D28, every 28 days, cycle 1-12; Zuberitamab: intravenously administered on day 1 of the c...